CCCC Q4 2021 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+143.0% YoY

Gross Profit

-$6M-32.2% margin

Operating Income

-$15M-76.0% margin

Net Income

-$16M-78.0% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

+136.2%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$507M

Total Liabilities

$117M

Stockholders' Equity

$390M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$8M	+143.0%
Gross Profit	-$6M	-$12M	+46.8%
Operating Income	-$15M	-$19M	+19.3%
Net Income	-$16M	-$22M	+28.2%